IM Cannabis: 66% Revenue Growth In Germany, Narrows EBITDA Loss In Q3
IM Cannabis: 66% Revenue Growth In Germany, Narrows EBITDA Loss In Q3
International medical cannabis company IM Cannabis Corp. (NASDAQ:IMCC) (CSE:IMCC) announced its financial results on Thursday for the third quarter ended Sept. 30, 2024.
國際醫療大麻公司Im Cannabis Corp.(納斯達克:IMCC)(cse:IMCC)於週四發佈了截至2024年9月30日第三季度的財務業績。
The company reported revenue from Germany grew 66% year-over-year, reaching CA$5.8 million ($4.1 million).
該公司的來自德國的營業收入同比增長66%，達到了580萬加元（410萬美元）。
"While the 66% growth we delivered in Germany, to reach $5.8M this quarter is a highlight, we spent the quarter focused on building a solid foundation for 2025," said CEO Oren Shuster. "Our goal was to build a strong, consistent supply chain, along with a laser focus on how to improve the efficiency and accuracy of how we use our resources. I believe that the foundation we built this quarter will be the basis we will use to deliver in 2025."
「雖然我們在德國實現了66%的增長，本季度達到了580萬加元，這是一大亮點，但我們專注於爲2025年打下堅實基礎，」首席執行官奧倫·舒斯特表示。「我們的目標是建立一個強大而一致的供應鏈，並專注於如何提高我們資源的使用效率和準確性。我相信，我們本季度建立的基礎將是我們在2025年交付的基礎。」
Read Also: IM Cannabis Soars: German Sales Surge 200% In First 3 Months Post-Legalization, Q2 Revenue Up 12% YoY
另請閱讀：Im Cannabis股價飆升：德國銷售在合法化後頭三個月激增200%，第二季度營業收入同比增長12%
- Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter here. If you're serious about the business, you can't afford to miss out.
- 訂閱本新聞快訊，每天免費獲取Benzinga獨家分析和大麻股行業及市場的最新資訊。如果您對業務認真，不容錯過。在這裏訂閱我們的新聞簡報。
Q3 Financial Highlights
Q3財務亮點
- Revenue increased by 12% year-over-year to CA$13.9 million, compared to CA$12.4 million in the third quarter of 2023.
- Gross profit was CA$3.1 million, up from CA$2.6 million in the prior year's period.
- Selling and marketing expenses dropped by 41% over the same period to CA$1.5 million.
- Total operating expenses fell by 16% year-over-year to CA$4.1 million.
- EBITDA loss narrowed by 68% over the period, from a loss of CA$1.6M in the third quarter of 2023 to a loss of CA$0.5 million in the third quarter of 2024. Adjusted EBITDA loss also improved by 82%, down to CA$0.2 million.
- The operational expense ratio improved by 25% year-over-year, falling from 40% in the third quarter of 2023 to 30% in the third quarter of 2024, reflecting improved cost management.
- Net loss narrowed to roughly CA$1 million from CA$2.1 million in the prior year's period.
- 營業收入同比增長12%，達到1390萬加元，而2023年第三季度爲1240萬加元。
- 毛利潤爲310萬加元，上年同期爲260萬加元。
- 銷售和市場營銷費用同比下降41%，降至150萬加元。
- 總營業費用同比下降16%，降至410萬加元。
- EBITDA虧損縮小68%，從2023年第三季度的160萬加元虧損減少至2024年第三季度的50萬加元虧損。調整後的EBITDA虧損也改善了82%，降至20萬加元。
- 運營費用比例同比改善25%，從2023年第三季度的40%降至2024年第三季度的30%，反映了成本管理的改善。
- 淨虧損從去年的210萬加元縮小至大約100萬加元。
IMCC Price Action
IMCC價格動態
IM Cannabis' shares traded 13.96% lower at $2.5339 per share at the time of writing on Thursday morning.
Im Cannabis的股份在週四上午的交易中下跌了13.96%，每股交易價格爲2.5339美元。
- IM Cannabis' $1.6M Non-Brokered Private Placement Offering, Here's What Investors Need To Know
- 在大麻股的160萬美元非經紀人私募股權投資中，這是投資者需要知道的內容
